Gonul 1999.

Methods	Four‐week double blind, randomised study.
Participants	Patients with major depression (DSM‐IV). Age: mean 35.6 years old (SD 11.8). Exclusion criteria: psychotic symptoms, catatonia.
Interventions	Fluvoxamine: 40 participants. Fluoxetine: 40 participants. Paroxetine: 40 participants. Sertraline: 40 participants. Fluvoxamine dose: 150 mg/day. Fluoxetine dose: 20 mg/day. Paroxetine dose: 20 mg/day. Sertraline dose: 50 mg/day.
Outcomes	HRSD. Total dropout, dropout due to side effects.
Funded by pharmaceutical companies	Unclear.
Fluvoxamine as an investigational or comparator drug	Unclear.
Notes	Patients with "major depression" (DSM‐IV) were included, so there might be some bipolar depression, but correct number was not reported. No clinical efficacy data could be entered in a meta ‐analysis; study authors reported only as "When the number of patients responding therapy was taken into account for the efficacy to each SSRI, we could not find any significant difference among them".
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Quote: "randomized", no further details.
Allocation concealment (selection bias)	Unclear risk	No details.
Blinding (performance bias and detection bias) All outcomes	Unclear risk	Quote: "single blind", no further details.
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Study endpoint: 3/40 missing from fluvoxamine group (3 due to adverse effects); 4/40 missing from fluoxetine group (4 due to adverse effects); 6/40 missing from paroxetine group (6 due to adverse effects); 4/40 missing from sertraline group (6 due to adverse effects).
Selective reporting (reporting bias)	High risk	Results of HRSD were not reported.